Cantel Medical Corp. Keeps Pace on Its Goal

Cantel Medical (NYSE: CMD) reported results for the first quarter, posting double-digit revenue and earnings growth to start its fiscal year. It's hard to ask for more from the medical-supply company.

Cantel Medical results: The raw numbers

What happened with Cantel Medical this quarter?

• Sales of endoscopy products led the group with revenue growth of 19.8%. Some of that came from the addition of BHT, a German company Cantel acquired in August. But even backing out acquisitions, endoscopy sales of grew 10.7% organically. A lot of the growth is coming from the installed base of endoscopy machines driving recurring revenue, which increased 20.8% year over year.
• Water purification and filtration sales increased 7.4%, and the unit still has a backlog of $66 million worth of products that have been ordered but need to be shipped and installed.
• Sales of healthcare disposables increased 5.7%, but income from the segment increased at a higher rate thanks to higher-margin branded products.
• The company generated $30.1 million in cash from operations, up 20.7% year over year, helping it pay down $19.3 million of debt. Net debt now sits at $130.8 million.

What management had to say

Jorgen Hansen, Cantel's president and CEO, said the company isn't done making acquisitions yet and hinted they could come sooner rather than later:

Hansen also highlighted some new products the company is working on to boost revenue organically:

Looking forward

Management is sticking with guidance for its current fiscal year that was given when it reported last quarter. Revenue should grow between 12.5% and 13.5%, with earnings per share (EPS) expected to grow by 20% to 25% while adjusted EPS will should increase only 10% to 13%.

As long as Cantel can keep doing what it did in the first fiscal quarter, it should be able to hit those goals.

10 stocks we like better than Cantel MedicalWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Cantel Medical wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of December 4, 2017

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool recommends Cantel Medical. The Motley Fool has a disclosure policy.